AnticoagEvaluator vs MAPPP
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
AnticoagEvaluator
This medical app assists healthcare professionals in making informed decisions regarding antithrombotic therapy for patients with non-valvular atrial fibrillation. It calculates patient risk factors, provides guideline-driven therapy recommendations, and helps optimize anticoagulant dosages.
- Calculate renal function and stroke/bleed risk
- Review ACC/AHA/HRS guideline therapy
- Generate individualized antithrombotic risk
- Optimize DOAC dosages
- Based on SPARC Tool
Read full descriptionHide full description
Make well-informed decisions on antithrombotic therapy for your non-valvular AF patients with the updated AnticoagEvaluator. Use the app to: • Calculate a patient's renal function and risk of ischemic stroke, thromboembolism, and bleed • Review ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention • Generate individualized risk for antithrombotic therapy options based on individual clinical trials. • Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics. This app is based on SPARC Tool, developed by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at www.sparctool.com
MAPPP
This medical guide assists clinicians in managing patients on anticoagulation therapy undergoing surgery or invasive procedures. It helps evaluate bleeding and thrombosis risks, guiding decisions on interrupting anticoagulation and using bridging therapy.
- Evaluate bleeding and thrombosis risk
- Guide anticoagulation interruption
- Provide bridging therapy guidance
- Detail drug dosing
- Offer laboratory monitoring advice
- Encourage clinician communication
Read full descriptionHide full description
Despite the considerable efficacy of antithrombotics and the increased number of oral anticoagulants now available, preventable bleeding and thrombotic events are still unacceptably common. While recently marketed agents require less laboratory monitoring, problems with the clinical management of anticoagulated patients persist, particularly in the peri-procedural period. Surgery and invasive medical interventions increase the risk of bleeding, while withholding anticoagulants increases the risk of thrombosis due to the underlying condition(s) for which anticoagulation was originally prescribed. The clinical team must therefore balance these competing risks and make educated decisions regarding the decision to interrupt oral anticoagulation for a medical procedure and, if interrupted, whether to "bridge" anticoagulation with injectable anticoagulants, such as low molecular weight heparin (LMWH) in warfarin treated patients. This guide is intended to: -Assist clinicians in the simultaneous evaluation of procedure-related bleeding risk and underlying risk of thrombosis -Guide decisions regarding the interruption of anticoagulation and the use of anticoagulant "bridging" -Provide detailed guidance for drug dosing and laboratory monitoring in the peri-procedural period -Encourage clear communication between clinicians involved in prescribing anticoagulants and performing invasive procedures This material was created by the multidisciplinary members of the Peri-Procedural Task Force of the New York State Anticoagulation Coalition and IPRO, the Medicare Quality Improvement Organization for New York State, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents do not necessarily reflect CMS policy. 10SOW-NY-AIM-7.3-14-01
Screenshots
Verdict
The clearest difference is rating: MAPPP at 4.2 against AnticoagEvaluator's 2.3. MAPPP also leads on review sentiment (50% vs 30%). AnticoagEvaluator's advantage is iOS requirement (11.0 vs 13.0). On price, ratings volume, update cadence and ads there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
MAPPP holds the better App Store score, 4.2 against 2.3. Both are backed by a comparable volume of ratings — 3 and 5 respectively. Written reviews point the same way: 30% of AnticoagEvaluator's written reviews are positive against 50% of MAPPP's.
AnticoagEvaluator ships an update every 7 months, MAPPP every 4 months. The most recent releases landed on June 3, 2026 and September 10, 2026 respectively.
| Parameter | AnticoagEvaluator | MAPPP |
|---|---|---|
| Price | Free | Free |
| Rating | 2.3 (3 ratings) | 4.2 (5 ratings) — better |
| Positive reviews | 30.0% of reviews | 50.0% of reviews — better |
| Number of ratings | 3 | 5 — better |
| Update frequency | Every 7 months | Every 4 months — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | Free |
| Devices | iPhone, iPad, iPod | iPhone, iPad, iPod |
| Requires iOS | 11.0 — better | 13.0 |
| Further details — not scored | ||
| Size | 25 MB | 54 MB |
| Age rating | 17+ | 17+ |
| Developer | American College of Cardiology | Island Peer Review Organization, Inc |
Customer experience
AnticoagEvaluator
MAPPP
In-app purchases
AnticoagEvaluator
No in-app purchases
MAPPP
No in-app purchases
Questions
Is AnticoagEvaluator free?
Is MAPPP free?
Which has better reviews, AnticoagEvaluator or MAPPP?
Do AnticoagEvaluator or MAPPP have ads?
Which is updated more often, AnticoagEvaluator or MAPPP?
Other comparisons















